Skip main navigation

Reoperation for Bleeding in Patients Undergoing Coronary Artery Bypass Surgery

Incidence, Risk Factors, Time Trends, and Outcomes
and on behalf of the Society of Thoracic Surgeons National Cardiac Surgery Database Investigators
Originally publishedhttps://doi.org/10.1161/CIRCOUTCOMES.109.858811Circulation: Cardiovascular Quality and Outcomes. 2009;2:583–590

Abstract

Background— Reoperation for bleeding represents an important complication in patients undergoing coronary artery bypass surgery (CABG). Yet, few studies have characterized risk factors and patient outcomes of this event.

Methods and Results— We evaluated 528 686 CABG patients at >800 hospitals in the Society of Thoracic Surgeons National Cardiac Database (2004 to 2007). Clinical features and in-hospital outcomes were evaluated in patients with and without reoperation for bleeding after CABG. Logistic regression was used to identify predictors of risk of this event and to estimate weights for an additive risk score. A total of 12 652 CABG patients (2.4%) required reoperation for bleeding. These rates remained fairly stable over time (2.2%, 2.3%, 2.5%, and 2.4% from 2004 to 2007, respectively). Although overall operative mortality was 4.5-fold higher in patients requiring reoperation for bleeding versus those who did not (2.0% versus 9.1%), this mortality risk declined significantly over time (11.3%, 9.5%, 8.8%, and 8.2% from 2004 to 2007, respectively, P for trend=0.0006). Factors associated with higher risk for reoperation were identified by multivariable analysis (c statistic=0.60) and summarized into a simple bedside risk score. The risk-score performed well when tested in the validation set (Hosmer-Lemeshow P=0.16).

Conclusions— Reoperation for bleeding remains an important morbid event after CABG. Nonetheless, death in patients with this complication has decreased over time. Our risk tool should allow estimation of patients risk for reoperation for bleeding and promote preventive measures when feasible in this at-risk group.

Reoperation for bleeding is required in 2.3% to 8% patients undergoing coronary artery bypass graft (CABG) surgery.1–9 Prior studies have characterized the morbidity and mortality and risk factors associated with the need for reoperation for bleeding after CABG.1–4,7–9 However, this information tends to be derived single tertiary center reports1–3,5,7–9 or from selected regional consortium.4,6 Additionally, these studies also preceded the use of more potent antithrombotic therapies such as clopidogrel and glycoprotein IIb/IIIa inhibitors that have been shown to increase reoperation for bleeding in patients undergoing CABG.10–12 Thus, the incidence, risk factors, and outcomes of patients requiring reoperation after CABG in contemporary community practice at large in recent era are not known.

Using the data from the Society of Thoracic Surgeons National Cardiac Surgery Database (STS NCD),13–15 we sought to (1) characterize the clinical features and in-hospital outcomes of patients undergoing CABG requiring reoperation for bleeding; (2) identify trends in reoperations and mortality in patients with this event; (3) explore the underlying plausible mechanisms for these trends; (4) identify preoperative clinical variables associated with the risk of this event; and (5) create a bedside tool to estimate the risk of this event.

Methods

STS NCD

The formation, rationale, and methodology of the STS NCD have been previously published.13–15 Briefly, this registry was initiated in 1986 with a goal to provide participants with their risk-adjusted outcomes compared to the national experience. This information is used by member institutions as a part of their continuous quality improvement efforts to help design strategies to improve their outcomes.

Patient Population

We analyzed data on patients aged ≥20 and ≤99 years undergoing isolated CABG from January 1, 2004, through December 31, 2007, at participating sites. Patients undergoing isolated or concomitant valve, congenital heart, or aortic surgery were excluded from the analysis. We also excluded patients if they had missing information on few key variables (ie, age, gender, status of surgery, surgery date, and hospital number).

Data Definitions

The STS NCD collects information on reoperation for bleeding as repeat surgery needed for bleeding or cardiac tamponade either before hospital discharge or between hospital discharge and within 30 days of their index operation if discharged earlier than 30 days. Information on all other adverse events was ascertained as in-hospital events. Detailed definitions of risk factors and adverse events were as provided on the STS web site (www.sts.org).

Statistical Analysis

Summary statistics are presented as frequency and percentage, or as median and interquartile range. χ2 test was used for comparing categorical variables and Wilcoxon rank sum test for continuous variables, both tests were stratum adjusted by participant ID. The Cochran-Mantel-Haenszel test was used for the analysis of trends.

Time Trends in Bleeding Risk

Time trends in risk-adjusted bleeding rates were assessed using a nonparsimonious multivariable logistic regression model with adjustment for 26 patient preoperative characteristics. Variables for this model were selected based on the previously published STS mortality model as well as clinical experience of factors and treatments known to be associated with increased risk of this event.14 These variables included age; gender; race; body surface area; hypertension; diabetes; immunosuppressive therapy; peripheral vascular disease; chronic lung disease; cerebrovascular disease; atrial fibrillation; baseline myocardial infarction, unstable angina, creatinine, heart failure, shock, dialysis, and left ventricular ejection fraction; left main disease; number of coronary artery disease; number of prior cardiac operations; percutaneous coronary interventions <6 hours of CABG; intraaortic balloon pump; status of surgery; year of operation and use of oral antiplatelet agents and intravenous glycoprotein IIb/IIIa receptor antagonists <24 hours of surgery. To account for clustering of outcomes within hospitals, the model was fitted using generalized estimating equation methodology with an exchangeable working correlation structure and empirical sandwich standard error estimates.

Risk-Adjusted Mortality

Mortality rates for patients needing reoperation were adjusted to account for risk factors present at the time of the initial operation. A nonparsimonious logistic regression model was developed for this purpose that included all factors listed above for the reoperation model with the exception of year of surgery and the use of oral antiplatelet agents and intravenous glycoprotein IIb/IIIa receptor antagonists <24 hours of surgery. We treated operative mortality as the dependent (outcome) variable. Indirectly standardized mortality rates were then calculated as the observed number of deaths divided by the model-predicted number of deaths multiplied by the overall mortality rate in the study sample.

Development of Predictive Models

We also developed a parsimonious logistic regression model that can be used to predict an individual patient’s risk of reoperation for bleeding using a small number of predictor variables. Parsimony was felt to be desirable to reduce the data collection burden for users of the model and to facilitate ease-of-use at the patient’s bedside. We used 80% of the sample for the development of the model and the remaining 20% of the sample for model validation. To enhance usability, continuous variables were assumed to have a linear relationship (age [in 5-year increments], body mass index) or categorized (serum creatinine, left ventricular ejection fraction).

Nonsignificant variables were eliminated using a backwards selection algorithm with a P=0.05 stopping rule.

Bedside Tool

In addition, we created a bedside tool which allows a crude estimate of risk of reoperation for bleeding to be calculated using simple addition based on a minimal number of explanatory variables. To choose variables for the bedside tool, we identified the smallest subset of predictors that were able to capture at least 90% of variation in the predicted log-odds of reoperation as estimated by the logistic predictive model described above. Regression coefficients were then converted to whole integers by multiplying the coefficients by a factor of 10 and rounding to the nearest integer to create a bedside risk prediction tool. For each possible risk score, the risk of reoperation for bleeding was estimated by averaging the predicted values from the logistic predictive model among all patients having the same risk score. Validation of risk score tool was performed by comparing observed mortality in the validation set versus expected mortality among risk score categories. The heterogeneity of the risk of this event among patients having the same risk score was assessed by plotting the distribution of predicted risk based on the full model within risk score subgroups. Calibration of model was assessed by Hosmer-Lemeshow test statistic.

Missing Data

Records with missing values of gender (0.01%), hospital number (0.002%), and operative status (0.07%) were excluded from all data presented here. Among the variables that were used for multivariable analysis, missing data were highest for ejection fraction (4.5%). Information for the remaining variables in the multivariable analyses was missing in <1%. Missing values of body surface area (0.49%) were imputed to gender-specific median values. Ejection fraction was imputed to the conditional median after stratifying by gender, status, and heart failure. Missing values of categorical risk factors were defaulted to their most common value which in most cases was “not present.” All analyses were performed using SAS 9.1 (SAS Institute) software.

Results

Baseline Clinical Characteristics of Patients Undergoing CABG Needing Reoperation for Bleeding

Repeat surgery for bleeding was required in 12 652 (2.39%) of 528 686 patients undergoing CABG. Patients needing reoperation for bleeding were significantly older, males, nonwhites with lower body mass index with higher comorbid conditions (Table 1). Similarly, preoperative features portending adverse prognosis (ie, myocardial infarction ≤24 hours of surgery, congestive heart failure, cardiogenic shock, lower creatinine clearance) were also significantly higher in this cohort. The use of potent antiplatelet agent (ie, thienopyridine or glycoprotein IIb/IIIa agent) within 24 hours before the operation was significantly higher in patients needing reoperation for bleeding. More patients who underwent emergent or emergent salvage surgery required reoperation for bleeding. Cardiopulmonary bypass use and the median pump and cross-clamp times were marginally higher among patients requiring reoperation for bleeding, whereas internal mammary artery bypass conduit use was less frequent among these patients. There was modest direct relationship between perfusion time and the rates of reoperation for bleeding (r=0.69). Reoperation for bleeding was required in 2.07% of patients undergoing off-pump CABG and in 2.47% of patients undergoing on-pump CABG (adjusted rates 2.06% versus 2.46%, P<0.0001). In patients who did receive clopidogrel before surgery, reoperation for bleeding was lower in the off-pump CABG patients compared with those undergoing on-pump CABG (3.68% versus 3.23%, P<0.001).

Table 1. Patient Characteristics

CharacteristicsOverallNo Reoperation for BleedingReoperation for BleedingP Value
IABP indicates intraaortic balloon pump; IQR, interquartile range; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; MI, myocardial infarction; and CHF, congestive heart failure.
Sample size528 686516 03412 652
Demographics
    Age, median (IQR), y65 (57–73)65 (57–73)68 (59–76)<0.0001
    Females, n (%)143 303 (27.1)140 136 (27.2)3167 (25.0)<0.0001
    Whites, n (%)450 862 (85.3)440 331 (85.3)10 531 (83.2)<0.0001
    BMI, median (IQR), kg/m228.6 (26–33)28.6 (26–33)27.4 (25–31)<0.0001
Medical history
    Hypertension, n (%)429 184 (81.2)418 861 (81.2)10 323 (81.6)0.4412
    Diabetes mellitus, n (%)198 771 (37.6)194 448 (37.7)4323 (34.2)<0.0001
    Current smoker, n (%)129 829 (24.6)126 915 (24.6)2914 (23.0)<0.0001
    Hypercholesterolemia, n (%)414 403 (78.4)404 713 (78.4)9690 (76.6)<0.0001
    Chronic lung disease, n (%)112 561 (21.3)109 622 (21.2)2939 (23.2)<0.0001
    Preoperative renal failure, n (%)30 089 (5.7)29 044 (5.6)1045 (8.3)<0.0001
    Preoperative dialysis, n (%)1.81.72.5<0.0001
    Stroke, n (%)37 642 (7.1)36 550 (7.1)1092 (8.6)<0.0001
    Immunosuppressive treatment, n (%)10 517 (2.0)10 147 (2.0)370 (2.9)<0.0001
    Peripheral vascular disease, n (%)80 511 (15.2)78 266 (15.2)2245 (17.7)<0.0001
    Cerebrovascular disease, n (%)72 497 (13.7)70 376 (13.6)2121 (16.8)<0.0001
    Prior CABG, n, (%)21 704 (4.1)21 001 (4.1)703 (5.6)<0.0001
    Prior PCI, n (%)114 664 (21.7)111 653 (21.6)3011 (23.8)<0.0001
Preoperative cardiac status and angiographic findings
    MI within 7 days126 705 (24.0)123 287 (23.9)3418 (27.0)<0.0001
    Cardiogenic shock2.01.94.2<0.0001
    PCI <6 h of CABG1.01.01.9<0.0001
    CHF13.313.216.7<0.0001
    Serum creatinine, median (IQR), mg/dl528 686 (1.0 [0.9–1.2])516 034 (1.0 [0.9–1.2])12 652 (1.1 [0.9–1.3])<0.0001
    Glomerular filtration rate, ml/min/1.73m2523 146 (73.1 [59–88])510 648 (73.1 [59–88])12 528 (69.7 [55–86])<0.0001
    Mitral regurgitation (moderate or severe), n (%)14 750 (2.8)14 214 (2.8)536 (4.2)<0.0001
    Aortic stenosis, n (%)8494 (1.6)8218 (1.6)276 (2.2)<0.0001
    Left main disease >50%, n (%)162 299 (30.7)158 142 (30.7)4157 (32.9)<0.0001
    Coronary artery disease ≥2 vessels, n (%)526 601 (99.6)513 990 (99.6)12 611 (99.7)0.1532
    LVEF, median (IQR), %528 686 (50 [45–50])516 034 (50 [45–50])512 652 (0 [40–50])<0.0001
Preoperative medications
    Aspirin, n (%)401 113 (75.9)391 243 (75.8)9870 (78.0)<0.0001
    Thienopyridines and/or glycoprotein IIb/IIIa antagonists, n (%)<0.0001
        Both, n (%)6390 (1.2)6071 (1.2)319 (2.5)
        Only glycoprotein IIb/IIIa antagonists, n (%)22 017 (4.2)21 429 (4.2)588 (4.7)
        Only thienopyridines, n (%)48 787 (9.2)47 128 (9.1)1659 (13.1)
        Neither, n (%)451 492 (85.4)441 406 (85.5)10 086 (79.7)
    Coumadin, n (%)2.43.02.4<0.0001
    Any intravenous anticoagulant, n (%)185 868 (35.2)180 972 (35.1)4896 (38.7)<0.0001
Operative details
    Status of surgery<0.0001
        Emergent salvage, n (%)1177 (0.22)1080 (0.21)97 (0.77)
        Emergent, n (%)24 586 (4.7)23 560 (4.6)1026 (8.1)
        Urgent, n (%)250 651 (47.4)244 472 (47.4)6172 (48.8)
        Elective, n (%)251 921 (47.7)246 578 (47.8)5343 (42.3)
    Cardiopulmonary bypass, n (%)423 677 (80.1)413 196 (80.1)10 481 (82.8)<0.0001
    Perfusion time, Median (IQR), min420 672 (91 [71–116])410 238 (91 [71–116])10 434 (97 [74–125])<0.0001
    Internal mammary artery graft, n (%)480 581 (90.9)469 641 (91.0)10 940 (86.5)<0.0001

In-Hospital Outcomes

Reoperation for bleeding after CABG was associated with worse outcomes compared with those without this event (Table 2). Those requiring reoperation were at higher risk for permanent stroke (2.2-fold), pneumonia (2.9-fold), septicemia (4.3-fold), and the need for prolonged ventilation (≥48 hours; 4.6-fold). Operative mortality was >4.5-fold in patients needing reoperation for bleeding. Even after adjusting for baseline confounders, mortality remained higher among patients needing reoperation for bleeding compared with those not requiring this (adjusted rates, 5.92% versus 1.97%, P<0.0001).

Table 2. Outcomes

CharacteristicsOverallNo Reoperation for BleedingReoperation for BleedingP Value
RBC indicates red blood cell; IABP, intraaortic balloon pump; and IQR, interquartile range.
Sample size, n (%)
Operative mortality, n (%)11 223 (2.1)10 072 (2.0)1151 (9.1)<0.0001
Total mortality, n (%)12 327 (2.3)11 115 (2.2)1212 (9.6)<0.0001
Permanent stroke, n (%)6479 (1.2)6148 (1.2)331 (2.6)<0.0001
Perioperative myocardial infarction, n (%)6037 (1.1)5822 (1.1)215 (1.7)<0.0001
Prolonged ventilation, n (%)53 465 (10.1)48 106 (9.3)5359 (42.4)<0.0001
Pneumonia, n (%)16 560 (3.1)15 455 (3.0)1105 (8.7)<0.0001
Cardiac tamponade, n (%)966 (0.18)287 (0.06)679 (5.37)<0.0001
Any blood product use, n (%)312 819 (59.2)300 634 (58.3)12 185 (96.3)<0.0001
Any RBC transfusion given, n (%)285 496 (54.0)273 705 (53.0)11 791 (93.2)<0.0001
Any platelet transfusion, n (%)116 259 (22.0)106 824 (20.7)9435 (74.6)<0.0001
Any fresh frozen plasma, n (%)93 187 (17.6)84 130 (16.3)9057 (71.6)<0.0001
Any cryoprecipitate, n (%)21 117 (4.0)17 292 (3.4)3825 (30.2)<0.0001
IABP use, n (%)52 772 (10.0)50 348 (9.8)2424 (20.2)<0.0001
Deep sternal wound infection, n (%)1982 (0.4)1768 (0.3)214 (1.7)<0.0001
Septicemia, n (%)5227 (1.0)4739 (0.9)488 (3.8)<0.0001
Postoperative length of stay, median (IQR), d527 276 (5.0 [4–7])514 661 (5.0 [4–7])12 615 (7 [5–12])<0.0001

Time Trends for Reoperation for Bleeding and Outcomes in Patients Undergoing CABG From 2004 to 2007

There were some minor shifts in the risk profiles of patients undergoing CABG overtime. For example, there was a clinically insignificant small increase in preprocedural thienopyridines use (9.1%, 8.9%, 9.7%, and 9.2% for years 2004 to 2007, respectively, P for trend 0.0018) and a decline in glycoprotein IIb/IIIa use over the study period (4.4%, 4.5%, 4.0%, and 3.9% for years 2004 to 2007 respectively, P for trend <0.0001). The rates of emergent salvage or emergent operations; proportion of patients undergoing CABG <24 hours of a myocardial infarction and rates of off-pump CABG remained stable over the study period. Overall, the risk profile of patients receiving CABG remained stable over the 4-year study period (predicted mortality risk 2.1%, 2.2%, 2.1%, and 2.1%, for 2004 to 2007; respectively).

Reoperation for bleeding was also fairly constant over this period (2.21%, 2.34%, 2.49%, and 2.42% for years 2004 through 2007, respectively). This clinically insignificant trend for increasing need for reoperation for bleeding over time persisted even when adjusted for baseline confounders (odds ratio, 1.04; 95% CI, 0.96 to 1.12 for 2005; odds ratio, 1.09; 95% CI, 1.00 to 1.18 for 2006; odds ratio, 1.07; 95% CI, 0.97 to 1.17 for 2004 [referent]).

Mortality over the study period improved in overall patients undergoing CABG, but particularly among those needing reoperation for bleeding (Figure 1).

Figure 1. Trends in operative mortality in patients undergoing CABG over time (2004 to 2007). Overall CABG indicates in overall patients undergoing CABG; ReOP, in patients needing reoperation for bleeding; Un-Adj, unadjusted; and Adj, adjusted.

Risk Prediction Model and Bedside Risk Tool

Factors independently associated with reoperation for bleeding in patients undergoing CABG are shown in Table 3 (c index, 0.60). The Hosmer-Lemeshow probability value of the full model was 0.19 providing little evidence of poor fit and suggesting high concordance between predicted and observed values. The simplified model coefficients were converted to an additive risk score (Figure 2). Figure 3 displays a comparison between predicted risk of reoperation for bleeding based on bedside risk tool and observed rates in the risk score categories in the validation set. The risk score tool performed well in the validation set with good concordance between predicted values in the risk categories and the observed risk in this sample (Hosmer-Lemeshow P=0.16). Figure 4 displays the variability between the estimate of risk based on the full model and the estimated risk determined by the bedside risk tool in various risk score categories in the derivation data-set. The average absolute difference between the risks calculated by full model compared with estimates based on the risk scores was 0.30%. Overall there was good correlation between the estimation of risk with risk score and that estimated based on the full model (correlation coefficient 0.95).

Table 3. Parsimonious Logistic Regression Model Showing Preoperative Factors Associated With the Need for Reoperation for Bleeding After CABG

VariableOdds Ratio95% CI
PCI indicates percutaneous coronary intervention.
Age ≥60 y1.02(1.02–1.02)
Body surface area0.39(0.33–0.45)
Body surface area squared1.98(1.53–2.57)
Nonwhite1.16(1.08–1.24)
Urgent surgery1.09(1.04–1.15)
Emergent surgery1.50(1.34–1.67)
Emergent salvage surgery2.08(1.68–2.58)
Preoperative serum creatinine–continuous variable1.50(1.34–1.67)
Male1.39(1.32–1.47)
Preoperative dialysis2.15(1.78–2.60)
Thienopyridines <24 h of CABG1.46(1.37–1.56)
Thienopyridine and glycoprotein IIb/IIIa receptor antagonists <24 h of CABG1.89(1.66–2.16)
Intraaortic balloon pump or inotropic support1.25(1.16–1.35)
Nondiabetics1.16(1.11–1.21)
3 vessel coronary artery disease1.12(1.07–1.18)
Previous cardiovascular interventions1.35(1.24–1.46)
Cerebrovascular disease1.12(1.06–1.19)
Immunosuppressive therapy1.36(1.21–1.53)
Cardiogenic shock1.23(1.09–1.39)
Congestive heart failure1.09(1.03–1.15)
Chronic lung disease-moderate to severe1.11(1.03–1.19)
Peripheral vascular disease1.07(1.01–1.14)
PCI <6 hours of CABG1.20(1.01–1.42)
c index0.60

Figure 2. Bedside risk tool (Normogram) to estimate the need for reoperation in patients undergoing CABG. BSA indicates body surface area; IABP, intraaortic balloon pump; ADPi, adenosine diphosphate receptor blockers; GPIIb/IIIa, glycoprotein IIb/IIIa receptor antagonists; and CV, cardiovascular.

Figure 3. Predicted mortality based on bedside risk tool and observed rates in the risk score categories in the validation set.

Figure 4. The estimated risk based on the full model (5% to 95% range) and the average estimated risk determined by the bedside risk tool in various risk score categories in the derivation set. Vertical bars represent 5th to 95th percentiles of the predicted risk calculated using the full model.

Discussion

Findings of Current Investigation

Our study provides a national perspective on the need for reoperation for bleeding after CABG in recent contemporary practice when ubiquitous use of potent antithrombotic agents is a norm. Our data found that the incidence of this event is low (2.4%) and remained fairly constant overtime. Nonetheless, reoperation for bleeding remained strongly associated with greater morbidity and mortality even after accounting for baseline confounding factors. Although reoperation for bleeding was needed in <1 of every 40 patients undergoing CABG, this event was associated with 1 of every 10 deaths in these patients (10.3% of all CABG deaths). Most impressively, there was a significant decline in mortality over time in patients with this complication.

Our data provide some insight into the potential mechanisms for the stable risk of reoperation for bleeding in these patients. Unlike prior studies from the STS NCD15 and the Northern New England Cardiovascular Disease Study Group,16 we did not find an increasing risk of patients undergoing CABG in recent times. Similarly, factors shown to be associated with an increased risk of reoperation for bleeding4,5,8,9 (ie, the rates of emergent or emergent salvage procedures), CABG <24 hours of myocardial infarction and on-pump (versus off-pump) CABG remained stable over the study period. The rates of thienopyridine use before CABG also remained unchanged over this time. Thus, the overall stable risk of patients undergoing CABG in general along with stable rates of predictive factors for increased risk of reoperation described above may explain in part the stable incidence of reoperation for bleeding in patients undergoing CABG.

In contrast, we can only speculate the reasons for the decline in mortality associated with reoperation for bleeding. This decrease may have been partially related to the growing awareness of the potential detrimental bleeding related side effects of not only aspirin, but also the newer antiplatelet and antithrombotic agents,10–12 avoidance of CABG when feasible in stable patients until after the effect of these agents wear off, the increasing experience of surgeons in the management of these patients, meticulous hemostasis during surgery, the use of appropriate blood products along with ε amino caproic acid, aprotinin, or desmopressin in the perioperative period,17 and use of recently collected (rather than old) blood products18 when needed. Additionally, the quality improvement effort as part of the ongoing participation in STS NCD may also have contributed to this decline in mortality over time.

Finally, we also developed a parsimonious predictive model to identify patients with increased risk of reoperation for bleeding after CABG. This may be potentially useful to physicians in estimating patient-specific risk for reoperation for bleeding before undertaking the operation, for counseling during informed consent process as well as to promote preventive measures when feasible in this at-risk group. More importantly, this outcome varied across different centers that have different case-mix. Thus, the current risk tool specific to reoperation for bleeding would allow risk adjusted comparisons of different sites. This would facilitate targeted quality improvement initiatives at sites with high rates of reoperation.

Unlike prior studies that have demonstrated increased risk for reoperation with preoperative aspirin in patients undergoing CABG,19 we found no such risk with the use of aspirin <24 hours before CABG. These findings are consistent with that of a recent review which showed no increased perioperative risk of bleeding requiring reoperation with aspirin among observational studies and increased risk only with doses ≥325 mg per day among patients in randomized trials.20

We point out that although based on large number of patients undergoing CABG with more than 12 000 events (a much larger number than any of the previously published studies), the ability of our model was only fair in discriminating between patients needing versus those not needing reoperation for bleeding, highlighting the difficulty and challenge in accurately identifying such patients preoperatively. Many factors such as surgeon’s experience or the threshold for taking back patient to the operating room, the rapidity of bleeding, patients underlying hemodynamics, other patient comorbidities, the response to conservative medical treatments including transfusion and antifibrinolytic agents, etc that were not collected in the STS NCD may have partially accounted for this lack of good discriminatory ability. Despite this drawback, our risk score performed well in the independent validation set and provided reasonable estimate of the risk of this event.

Comparisons With Prior Studies

Many previous studies have provided insights into the need for reoperation for bleeding and have reported an incidence that varied from 2.3% to 8.0%.1–12 Our estimate of this risk is on the lower side (2.4%) of that described in these studies and perhaps reflects a stable estimate of the risk in community at large. Nonetheless, our data concurs with these previous studies in that reoperation for bleeding increases morbidity and mortality in patients undergoing CABG and remains an important target for improving outcomes.

Important differences between these previous studies and our investigation exist. Most prior studies involved patients at a single center 1–3,5,7,12 or those from a regional consortium involving few institutions,4,6 thus with few patients and fewer events. In contrast, our data involve current contemporary practice at more than 800 widely varying institutions with a very large number of patients and events allowing robust statistical power, thereby increasing the generalizability of our findings. More importantly, almost all of these studies predated the more routine use of potent antiplatelet and antithrombotic agents,1–5,8,9 an important and independent predictor of this event in this and other studies10–12 limiting their applicability in current era. Finally, few of these prior investigations focused on risk factors associated with increased risk of reoperation4,6,8 or provided a simple risk tool that could be used in routine practice for estimating risk of this adverse event in patients undergoing CABG.

Clinical Implications

Many newer antithrombotic and antiplatelet agents have completed phase III clinical trials or are on the verge of doing so and many more are in the early clinical phase of human studies.21–23 As these agents become engrained in contemporary cardiovascular practice, as accurate identification on admission of patients requiring reoperation after CABG remain a major ongoing challenge,24 and because the effectiveness of many therapies is reduced if not given early after admission,25 exposure to these potent agents before CABG (an already increasingly older and sicker population) is likely to increase. This is expected to increase the need for reoperation after CABG. Although the easiest option to minimize the risk is to avoid exposure to these agents before CABG or to delay surgery in those exposed until platelet function or hemostasis have recovered, this approach may not be pragmatic many times and may even have the potential for harm as well as increasing cost (of hospitalization) while awaiting CABG. Thus, if outcomes of CABG patients are to be improved in the future, continued ongoing efforts from surgical colleagues would be necessary to reduce the risk of perioperative bleeding. Our study is unable to provide insights into strategies that may be helpful in minimizing the risk of this adverse event in CABG patients. It is likely that understanding of the detail pharmocology and the duration of increased risk conferred by the exposure of these new agents, meticulous hemostasis in those exposed to these drugs, vigilance for bleeding, and aggressive management early on with appropriate blood products and drugs may have the potential for reducing the need for reoperation for bleeding after CABG. Whether shorter acting intravenous agents21,22 or the use of novel RNA-aptamer-drug-antidote combination23 or the use of off-pump CABG would allow efficacy upfront when needed and minimize postoperative bleeding after CABG remains to be established. Finally, the importance of quality improvement initiatives at individual institutions, regional, or national level to measure this event across various sites and compare them after accounting for patient case-mix using the current risk tool, identify the root cause of the problem at sites with high rates of this event, and then implement process changes to minimize it cannot be overemphasized to help reduce the risk of this event and improve outcomes of patients undergoing CABG.

Limitations

Although, the STS NCD now represents a majority of centers in United States, there is a slight overrepresentation of participation from larger centers and those with better overall outcomes. Second, we are only able to analyze risk factors collected and cannot account for the influence of any unmeasured factors influencing the risk of reoperation for bleeding in CABG patients. We only had information on the use of thienopyrines within 24 hours of CABG, but not before this time. However, this would only have biased our observation toward null (ie, no increased risk of bleeding with clopidogrel). The current database only allowed for evaluation of short-term risk, as we did not have any information on long-term outcomes.

Conclusions

Reoperation for bleeding is an important morbid event after CABG that has remained stable over time. Fortunately, death in patients with this adverse event decreased over time at least among patients undergoing CABG at institutions participating in STS NCD. The future availibility of more potent antiplatelet agents is expected to increase the risk of reoperation for bleeding in CABG patients further highlighting the ongoing need for monitoring and quality improvement efforts at institutional, regional, or national level through initiatives like the STS NCD to reduce this complication in the hope of improving ouctomes after CABG. Our risk tool may allow estimation of patients risk for reoperation for bleeding and promote preventive measures when feasible in this at-risk group.

Sources of Funding

This work was funded by the STS NCD.

Disclosures

None.

Footnotes

Correspondence to Rajendra H. Mehta, MD, Box 17969, Duke Clinical Research Institute, Durham, NC 27715. E-mail

References

  • 1 Unsworth-White MJ, Herriot A, Valencia O, Poloniecki J, Smith EEJ, Murday AJ, Parker DJ, Treasure T. Resternotomy for bleeding after cardiac operations: A marker for increased morbidity and mortality. Ann Thorac Surg. 1995; 59: 664–667.CrossrefMedlineGoogle Scholar
  • 2 Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg. 1996; 111: 1037–1046.CrossrefMedlineGoogle Scholar
  • 3 Sellman M, Intonti MA, Ivert T. Reoperations for bleeding after coronary artery bypass procedures during 25 years. Eur J Cardiothorac Surg. 1997; 11: 521–527.CrossrefMedlineGoogle Scholar
  • 4 Dacey LJ, Munoz JJ, Baribeau YR, Johnson ER, Lahey SJ, Leavitt BJ, Quinn RD, Nugent WC, Birkmeyer JD, O'Connor GT; for the Northern New England Cardiovascular Disease Study Group. Reoperation for hemorrhage following coronary artery bypass grafting-Incidence and risk factors. Arch Surg. 1998; 133: 442–447.CrossrefMedlineGoogle Scholar
  • 5 Frankel TJ, Stamou SC, Lowery RC, Kapetanakis EI, Hill PC, Haile E, Corso PJ. Risk factors for hemorrhage-related reexploration and blood transfusion after conventional versus coronary revascularization without cardiopulmonary bypass. J Cardiothorac Surg. 2005; 27: 494–500.CrossrefGoogle Scholar
  • 6 Munoz JJ, Birkemeyer NJO, Dacey LJ, Birkmeyer JD, Charlesworth DC, Johnson ER, Lahey SJ, Norotsky M, Quinn RD, Westbrook BM, O'Connor GT, for the Northern New England Cardiovascular Disease Study Group. Trends in rates of reexploration for hemorrhage after coronary artery bypass surgery. Ann Thorac Surg. 1999; 68: 1321–1325.CrossrefMedlineGoogle Scholar
  • 7 Choong CK, Gerrard C, Goldsmith KA, Dunningham H, Vuylsteke A. Delayed re-exploration for bleeding after coronary artery bypass surgery results in adverse outcomes. Eur J CardioThorac Surg. 2007; 31: 834–838.CrossrefMedlineGoogle Scholar
  • 8 Despotis GJ, Filos KS, Zoys TN, Hogue CW, Spitznagel E, Lappas DG. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: A multivariate analysis in cardiac surgical patients. Anesth Analg. 1996; 82: 13–21.MedlineGoogle Scholar
  • 9 Karthik S, Grayson AD, McCarron EE, Pullan DM, Desmond MJ. Reexploration for bleeding after coronary artery bypass surgery: risk factors, outcomes, and the effect of time delay. Ann Thorac Surg. 2004; 78: 527–534.CrossrefMedlineGoogle Scholar
  • 10 Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S; Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial. Benefits and risks of the combination of clopidogrel in patients undergoing surgical revascularization for Non-ST elevation acute coronary syndromes; The Clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial. Circulation. 2004; 110: 1202–1208.LinkGoogle Scholar
  • 11 Kapetanakis EI, Medlam DA, Petro KR, Haile E, Hill PC, Dullum MK, Bafi AS, Boyce SW, Corso PJ. Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae? Circulation. 2006; 113: 1667–1674.LinkGoogle Scholar
  • 12 Kapetanakis EI, Mediam DA, Boyce SW, Haile E, Hill PC, Dullum MKC, Bafi AS, Petro KR, Corso PJ. Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist’s panacea or the surgeon’s headache? Eur Heart J. 2005; 26: 576–583.CrossrefMedlineGoogle Scholar
  • 13 Edwards FH, Petersen ED, Coombs LP, DeLong ER, Jamieson WRE, Shroyer ALW, Grover FL. Prediction of operative mortality after valve replacement surgery. J Am Coll Cardiol. 2001; 37: 885–892.CrossrefMedlineGoogle Scholar
  • 14 Shroyer AL, Coombs LP, Peterson ED, Eiken MC, DeLong ER, Chen A, Ferguson TB Jr, Grover FL, Edwards FH; Society of Thoracic Surgeons. The Society of Thoracic Surgeons: 30-day operative mortality and morbidity risk models. Ann Thorac Surg. 2003; 75: 1856–1864.CrossrefMedlineGoogle Scholar
  • 15 Ferguson TB, Hamill PG, Peterson ED, DeLong ER, Glover FL. A decade of change—risk profiles and outcomes for isolated coronary artery bypass grafting procedures, 1990–1999: a report from the STS National Database Committee and the Duke Clinical Research Institute. Ann Thorac Surg. 2002; 73: 480–490.CrossrefMedlineGoogle Scholar
  • 16 Plume SK, O'Connor GT, Omstead EM. Changes in patients undergoing coronary artery bypass grafting:1987–1990: Update in 2000. Ann Thorac Surg. 2001; 72: 314–315.CrossrefMedlineGoogle Scholar
  • 17 Janssens M, Hartstein G, David JL. Reduction in requirements for allogenic blood products: pharmacologic methods. Ann Thorac Surg. 1996; 62: 1944–1950.CrossrefMedlineGoogle Scholar
  • 18 Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, Blackstone EH. Duration of red blood cell storage and complications after cardiac surgery. N Engl J Med. 2008; 358: 1229–1239.CrossrefMedlineGoogle Scholar
  • 19 Sethi GK, Copeland JG, Goldman S, Moritz T, Zadina K, Henderson WG. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. J Am Coll Cardiol. 1990; 15: 15–20.CrossrefMedlineGoogle Scholar
  • 20 Sun JC, Whitlock R, Cheng J, Eikelboom JW, Thabane L, Crowther MA, Teoh KH. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. Eur Heart J. 2008; 29: 1057–1571.CrossrefMedlineGoogle Scholar
  • 21 Angiolillo DJ, Guzzman LA. Clinical overview of promising nonthienopyridine antiplatelet agents. Am Heart J. 2008; 156: S23–S28.CrossrefMedlineGoogle Scholar
  • 22 Angiolillo DJ. ADP receptor antagonism: what’s in the pipeline? Am J Cardiovasc Drugs. 2007; 7: 423–432.CrossrefMedlineGoogle Scholar
  • 23 Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, Lin M, Walder J, Steinhubl SR, Gilchrist IC, Kleiman NS, Vorchheimer DA, Chronos N, Melloni C, Alexander JH, Harrington RA, Tonkens RM, Becker RC, Rusconi CP. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation. 2008; 117: 2865–2874.LinkGoogle Scholar
  • 24 Mehta RH, Chen AY, Pollack CV, Roe MT, Zalenski R, Delgado G, Gibler WB, Ohman EM, Harrington RA, Peterson ED. Challenges in predicting the need for coronary artery bypass grafting at presentation in patients with non-ST elevation acute coronary syndromes. Am J Cardiol. 2006; 98: 624–627.CrossrefMedlineGoogle Scholar
  • 25 Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 288: 2411–2420.CrossrefMedlineGoogle Scholar